BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, March 10, 2026
Home » Newsletters » BioWorld Asia

BioWorld Asia

July 18, 2012

View Archived Issues

IMI on the Move to Improve Drug Development in Europe

DUBLIN, Ireland – It has not been long since the first research programs got under way, but there is evidence already that projects undertaken by the €2 billion (US$2.4 billion) Innovative Medicines Initiative (IMI) are having an impact on the environment for drug development in Europe. Read More

New Target Identified to Block Cancer Metastasis, Study Shows

LONDON – The process by which tumors spread around the body involves a crucial molecular interaction between tumor cells in the bloodstream and the cells that line the blood vessels, a new study suggested. Read More

OSE Pharma Is Seeking to Revive Lung Cancer Vaccine

Orphan Synergy Europe (OSE) Pharma SA came out of the starting gate with a Phase II candidate, in-licensing a therapeutic cancer vaccine discovered at San Diego-based Epimmune Inc. that had languished following that company's 2005 merger with Immuno-Designed Molecules (IDM) SA, of Paris. Read More

RedX Pharma Raising $17M for Antiviral, Antibody Work

LONDON – RedX Pharma Ltd. is planning a £10.8 million (US$16.8 million) investment to extend the reach of its expertise in the structural modification of marketed drugs into antibiotics and antivirals. Read More

Watson, Venter Lead Genomic 'Rock Stars' Lineup at ESOF

DUBLIN, Ireland – As a general science meeting, the Euroscience Open Forum (ESOF) does a pretty good job of being all things to all men and all women. Read More

Cell Therapy Still Progressing Despite Multiple Challenges

DUBLIN, Ireland – Small molecules may be hard enough to get through development and registration, but that is nothing like the challenge the industry is facing in attempts to get cell therapies to market. Read More

Scientists Serve Up Realism Amid the Optimism at ESOF

DUBLIN, Ireland – Dublin's undpredictable weather, a confounding blend of sunshine, wind and rain, was an apt metaphor for the mix of optimism, realism and disappointment that could be heard in the many scientific sessions during the first full day of the Euroscience Open Forum 2012 (ESOF 2012) meeting at the Convention Centre Dublin Thursday. Read More

Other News To Note

• Ipsen SA, of Paris, said partner Inspiration Biopharmaceuticals Inc., of Cambridge, Mass., was notified that the FDA placed on hold both Phase III studies evaluating IB1001, an intravenous recombinant Factor IX therapy for the treatment and prevention of bleeding episodes in people with hemophilia B. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 9, 2026.
  • Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

    Cas and effect: Merck’s phase III ripples HIF-2α space

    BioWorld
    Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
  • Tanycytes in green capturing tau protein in red.

    Brain’s hidden tau-clearing pathway uncovered

    BioWorld Science
    Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 10, 2026
  • MSD synthesizes α-synuclein PET agents

    BioWorld Science
    Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing